The amplification of the gene for HER2 occurs in approximately 20 to 25% of breast cancers. The accurate measurement of this biomarker is important for the proper treatment with anti-HER2 therapeutics. Clinical laboratories are beginning to utilize accurate and sensitive diagnostic tests based on